How to work with the FDA on biosimilar approvals
This article was originally published in Scrip
Executive Summary
The US is still awaiting its first biosimilar approval application, and the FDA's draft guidelines have yet to be finalized, but behind the scenes many companies are well advanced in product development discussions with the agency, and the consensus seems to be that the first biosimilar submission will come sometime this year.